BioCentury | Jun 11, 2007
Company News

Sinclair, Bayer sales and marketing update

...Atopiclair in France and Italy. In Italy, Italfarmaco S.p.A. also has co-marketing rights from SPH. Chester Valley Pharmaceuticals Inc....
BioCentury | Nov 6, 2006
Clinical News

Sebclair regulatory update

...FDA granted 510(k) clearance to Sebclair to treat seborrheic dermatitis. Chester Valley (Malvern, Penn.) has U.S. marketing...
BioCentury | Nov 6, 2006
Finance

Ebb & Flow

...113.5p on the week after FDA granted 510(k) clearance to Sebclair to treat seborrheic dermatitis. Chester Valley...
BioCentury | Nov 3, 2006
Company News

FDA approves Sebclair for seborrheic dermatitis

...FDA granted 510(k) clearance to Sebclair from Sinclair (LSE:SPH) to treat seborrheic dermatitis. Chester Valley (Malvern, Penn...
BioCentury | Aug 1, 2005
Company News

Sinclair, Anabiosis Ltd., Chester Valley sales and marketing update

...SPH granted Chester Valley U.S. market rights to Sebclair to treat seborrheic dermatitis. SPH could receive $4...
...treat seborrheic dermatitis. SPH could receive $4 million in upfront and milestone payments, plus royalties. Chester Valley...
...terms were not disclosed. Sinclair Pharma plc (LSE:SPH), Godalming, U.K. Anabiosis Ltd. , Athens, Greece Chester Valley Pharmaceuticals Inc....
BioCentury | Dec 13, 2004
Company News

Chester Valley dermatology news

...Private equity firm GTCR Golder Rauner LLC (Chicago, Ill.) will form specialty dermatology company Chester Valley Pharmaceuticals...
...BDY, Fairfield, N.J.). Xavier Yon, former CEO of Galderma SA (Lausanne, Switzerland), will be chairman. Chester Valley Pharmaceuticals Inc....
BioCentury | Dec 7, 2004
Company News

GTCR to form Chester Valley Pharmaceuticals

...company Chester Valley Pharmaceuticals (Malvern, Penn.). GTCR will invest up to $75 million in the newco. Chester Valley...
Items per page:
1 - 7 of 7
BioCentury | Jun 11, 2007
Company News

Sinclair, Bayer sales and marketing update

...Atopiclair in France and Italy. In Italy, Italfarmaco S.p.A. also has co-marketing rights from SPH. Chester Valley Pharmaceuticals Inc....
BioCentury | Nov 6, 2006
Clinical News

Sebclair regulatory update

...FDA granted 510(k) clearance to Sebclair to treat seborrheic dermatitis. Chester Valley (Malvern, Penn.) has U.S. marketing...
BioCentury | Nov 6, 2006
Finance

Ebb & Flow

...113.5p on the week after FDA granted 510(k) clearance to Sebclair to treat seborrheic dermatitis. Chester Valley...
BioCentury | Nov 3, 2006
Company News

FDA approves Sebclair for seborrheic dermatitis

...FDA granted 510(k) clearance to Sebclair from Sinclair (LSE:SPH) to treat seborrheic dermatitis. Chester Valley (Malvern, Penn...
BioCentury | Aug 1, 2005
Company News

Sinclair, Anabiosis Ltd., Chester Valley sales and marketing update

...SPH granted Chester Valley U.S. market rights to Sebclair to treat seborrheic dermatitis. SPH could receive $4...
...treat seborrheic dermatitis. SPH could receive $4 million in upfront and milestone payments, plus royalties. Chester Valley...
...terms were not disclosed. Sinclair Pharma plc (LSE:SPH), Godalming, U.K. Anabiosis Ltd. , Athens, Greece Chester Valley Pharmaceuticals Inc....
BioCentury | Dec 13, 2004
Company News

Chester Valley dermatology news

...Private equity firm GTCR Golder Rauner LLC (Chicago, Ill.) will form specialty dermatology company Chester Valley Pharmaceuticals...
...BDY, Fairfield, N.J.). Xavier Yon, former CEO of Galderma SA (Lausanne, Switzerland), will be chairman. Chester Valley Pharmaceuticals Inc....
BioCentury | Dec 7, 2004
Company News

GTCR to form Chester Valley Pharmaceuticals

...company Chester Valley Pharmaceuticals (Malvern, Penn.). GTCR will invest up to $75 million in the newco. Chester Valley...
Items per page:
1 - 7 of 7